Ireland - English - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - mycophenolic acid - tablets gastro-resistant - 180 milligram - selective immunosuppressants

Malta - English - Medicines Authority

teva pharma b.v. (utrecht) swensweg 5, 2031 ga haarlem, netherlands - mycophenolic acid - gastro-resistant tablet - mycophenolic acid 180 mg - immunosuppressants

Malta - English - Medicines Authority

teva pharma b.v. (utrecht) swensweg 5, 2031 ga haarlem, netherlands - mycophenolic acid - gastro-resistant tablet - mycophenolic acid 360 mg - immunosuppressants

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mylan - mycophenolate mofetil - tablet - 500mg

Malta - English - Medicines Authority

novartis ireland limited vista building, elm park, merrion road, ballsbridge, dublin 4,, ireland - mycophenolic acid - gastro-resistant tablet - mycophenolic acid 360 mg - immunosuppressants

Malta - English - Medicines Authority

novartis ireland limited vista building, elm park, merrion road, ballsbridge, dublin 4,, ireland - mycophenolic acid - gastro-resistant tablet - mycophenolic acid 180 mg - immunosuppressants

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis ireland limited - mycophenolic acid - gastro-resistant tablet - 180 milligram(s) - selective immunosuppressants; mycophenolic acid

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis ireland limited - mycophenolic acid - gastro-resistant tablet - 360 milligram(s) - selective immunosuppressants; mycophenolic acid

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

sonke pharmaceuticals (pty) ltd - tablet - see ingredients - each tablet contains efavirenz 600,0 mg emtricitabine 200,0 mg tenofovir disoproxil fumarate 300,0 mg

European Union - English - myHealthbox

merck sharp & dohme limited - lamivudine, raltegravir potassium - film-coated tablets - 150 mg of lamivudine and 300 mg of raltegravir - hiv infections - antivirals for systemic use - indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infection in adults, adolescents, and children from the age of 6 years and weighing at least 30 kg without present or past evidence of viral resistance to antiviral agents of the insti (integrase strand transfer inhibitor) and nrti (nucleoside reverse transcriptase inhibitor) classes